Introduction
============

Cancer is a major public health problem all over the world because of its increasing incidence and mortality in recent years.[@b1-ott-12-479] According to Cancer Statistics, it was estimated that in 2017, 1,688,780 new cases of cancer and 600,920 cancer deaths were projected to occur in the US.[@b1-ott-12-479] In China, an estimated 4,292,000 new cases of cancer and 2,814,000 cancer deaths occurred in 2015.[@b2-ott-12-479] Lung, stomach, liver, and esophageal cancers were the most commonly diagnosed and were recognized as the foremost reasons of cancer death.[@b3-ott-12-479] Up to now, the gold standard for detecting and diagnosing cancers has been pathological biopsy, which has several limitations, including its invasive and unpleasant nature and the risk of cancer metastasis.[@b3-ott-12-479] Several blood-based clinical biomarkers are useful in the early detection and diagnosis of cancer, including prostate specific antigen, carcinoembryonic antigen, carbohydrate antigen 15-3, and alpha-fetoprotein.[@b4-ott-12-479]--[@b7-ott-12-479] However, their low specificity and sensitivity limit their clinical usage. Therefore, finding an effective tumor-specific biomarker for early detection and diagnosis of cancer is becoming urgent and vital.

miRNAs, a class of small, non-coding, endogenous, single-stranded RNAs of a length of 22 nucleotides, function as potential oncogenes or tumor suppressor genes and play vital regulatory roles in tumorigenesis and tumor progression.[@b8-ott-12-479],[@b9-ott-12-479] Accumulating evidence has demonstrated that blood-based miRNAs could serve as novel and noninvasive biomarkers for detecting and diagnosing patients with various cancers.[@b10-ott-12-479],[@b11-ott-12-479] miR-210, located on chromosome 11p15.5, contributes to the development of several cancers, including bladder cancer (BLCA), renal cell carcinoma (RCC), lung cancer (LC), and pancreatic cancer (PAAD).[@b12-ott-12-479] A number of studies have explored the possible clinical usage of miR-210 in detecting and diagnosing cancers. Due to limited sample sizes and variation in study design, the overall result is inconsistent and inconclusive. Although two previous meta-analyses about the diagnostic significance of miR-210 in cancer detection have already been published several years ago, there are some defects in these studies.[@b13-ott-12-479],[@b14-ott-12-479] First, the results of both meta-analyses may lack statistical power due to the limited number of eligible studies enrolled. Recently, a large number of new studies have been conducted to explore the accuracy of miR-210 in the detection and diagnosis of cancer. Second, one of the two meta-analyses explored the accuracy of miRNA-210 only in LC detection.[@b14-ott-12-479] To avoid the previously mentioned limitations, we conducted this pooled analysis to derive a more reliable conclusion of the overall accuracy of miR-210 in the detection and diagnosis of cancer.

Materials and methods
=====================

Identification of miR-210 associated with various cancers
---------------------------------------------------------

For identification of miR-210 expression in various cancers, we used SPSS-23 and GraphPad Prism 6 based on transcriptome profiling of TCGA with information of clinicopathological characteristics downloaded from UCSC Xena (<http://xena.ucsc.edu/>). All data from UCSC Xena were analyzed using the Student's *t*-test and the non-parametric test. The results are expressed as mean ± SD and *P*-values of less than 0.05 are considered as statistically significant.

Search strategy
---------------

The electronic databases PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang were searched to identify relevant papers about miR-210 and cancer published by October 20, 2017. The search terms were as follows: ("diagnosis" OR "sensitivity" OR "specificity" OR "ROC") and ("microRNA-210" OR "miRNA-210" OR "miR-210" OR "miR-210" OR "hsamir-210") and ("cancers" OR "carcinomas" OR "neoplasms"). Two reviewers (Anbang He and Song Feng) independently checked the abstract after the articles were found and read the full text if necessary to evaluate the quality of the articles. Conflicts of opinion between the two reviewers regarding the articles were resolved by other reviewers.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria included: 1) the diagnostic value of miR-210 in detecting cancer; 2) a case control group designed with benign tumors; and 3) sufficient data that could be extracted or calculated from the article to obtain diagnostic parameters. The exclusion criteria were as follows: 1) letters, reviews or meta-analyses; 2) not related to either miR-210 or cancer or diagnostic value; 3) insufficient data that could not be extracted or calculated from the article to obtain diagnostic parameters.

Data extraction and quality assessment
--------------------------------------

The necessary information from the eligible studies was extracted by two investigators independently. The data extracted from eligible studies were listed as follows: 1) first author, 2) year of publication, 3) country, 4) ethnicity, 5) cancer type, 6) normalizer, 7) sample type, 8) test method, 9) the value of the cutoff, 10) number of cases and controls, 11) the diagnostic parameters including true positive, false positive, false negative, and true negative. Moreover, information missing from the original articles was obtained by contacting the relevant corresponding author. Study quality was assessed according to Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) guidelines.[@b15-ott-12-479] The QUADAS-2 list was used on each article, with each answer being either "yes(Y)," "no(N)" or "unclear(U)."

Statistical analysis
--------------------

All the statistical analyses were performed by using Stata (StataCorp LP, College Station, TX, USA, version 13.0). The bivariate meta-analysis model was applied to our analysis to calculate pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic OR (DOR).[@b16-ott-12-479] We also established a summary receiver operator characteristic (SROC) curve and calculated the AUCs and 95% CI. These data were confirmed by a hierarchical SROC (HSROC) model.[@b17-ott-12-479] Spearman correlation coefficients and ROC plane analyses were conducted to evaluate the heterogeneity of the threshold effect.[@b18-ott-12-479] Heterogeneity of non-threshold effects was assessed using Cochran-Q and Inconsistency index (I[@b2-ott-12-479]) tests. A *P*-value less than 0.10 for the Q test or an I[@b2-ott-12-479] value higher than 50% indicated obvious heterogeneity between the studies. Meta-regression and subgroup analyses were applied to find out potential sources of heterogeneity. Fagan's nomogram was used to certify relationships between prior-test probability, likelihood ratio, and post-test probability. Deeks' funnel plot asymmetry test was used to assess potential publication bias.[@b19-ott-12-479]

Result
======

miR-210 expression and clinicopathological characteristics
----------------------------------------------------------

The clinicopathological characteristics of various cancers, including the expression of miR-210 (3 p and 5 p), overall survival, and relapse-free survival (RFS) were analyzed by using data from the UCSC Xena website. All results are shown in [Table 1](#t1-ott-12-479){ref-type="table"}. As shown in [Figure 1](#f1-ott-12-479){ref-type="fig"}, the expression of both miR-210-3p and miR-210-5p were up-regulated in BLCA, breast cancer (BRCA), kidney clear cell carcinoma (KIRC), kidney papillary cell carcinoma (KIRP), stomach cancer (STAD), and lung squamous cell carcinoma (LUSC) ([Figure 1](#f1-ott-12-479){ref-type="fig"}). Up-regulated miR-210-3p expression in KIRC was positively correlated with shorter RFS ([Table 1](#t1-ott-12-479){ref-type="table"}).

Literature search
-----------------

Three hundred and thirty-three potentially relevant articles were found using the PubMed, Cochrane Library, Web of Science, CNKI, and Wanfang databases. The abstracts of all of these studies and the full-text, if necessary, were checked by two reviewers; after duplicates, irrelevant articles, reviews or meta-analyses were excluded, 30 articles remained and were included in our meta-analysis as shown in [Figure 2](#f2-ott-12-479){ref-type="fig"}.

Data characteristics and quality assessment
-------------------------------------------

The necessary information from the 30 articles that were included, as shown in [Table 2](#t2-ott-12-479){ref-type="table"}, was extracted and included the following: 1) first author; 2) year of publication: ranged from 2009--2017; 3) country: one from Egypt, one from France, one from Germany, two from Japan, the rest of the studies from China; 4) ethnicity: 17 studies were Asian, eight studies were Caucasian/African, three studies were Caucasian, one study was African; 5) cancer type: included non-small-cell lung cancer: six studies, LC: four studies, BLCA: two studies, RCC: five studies, PAAD: six studies, colorectal carcinoma (CRC): two studies, BRCA: one study, gastric cancer (GC): one study, glioma: one study, leukemia: one study; 6) sample type: serum: 20 studies, sputum: five studies, urine: two studies, pancreatic juice: one study, fecal matter: one study; 7) test method: qRT-PCR: 28 studies, microarray: one study. We evaluated all of the included studies according to the QUADAS-2 tool. The results are summarized in [Table 3](#t3-ott-12-479){ref-type="table"}. We found that the overall quality of the studies included was relatively moderate.

Diagnostic accuracy of miR-210 for cancers
------------------------------------------

The pooled sensitivity and specificity of the studies overall were 0.74 (95% CI: 0.68--0.79) and 0.79 (95% CI: 0.74--0.83), respectively ([Figure 3](#f3-ott-12-479){ref-type="fig"}). Considering that the I[@b2-ott-12-479] values for sensitivity and specificity were 88.07% (95% CI: 84.69--91.44) and 79.44% (95% CI: 72.67--86.22), respectively, this suggests significant heterogeneity in sensitivity and specificity. The pooled PLR and NLR were 3.57 (95% CI: 2.85--4.47) and 0.32 (95% CI: 0.26--0.40), respectively ([Figure 4](#f4-ott-12-479){ref-type="fig"}). The DOR was 10.98 (95% CI: 7.55--15.98) ([Figure 5](#f5-ott-12-479){ref-type="fig"}). The area under the SROC curve was 0.84 (95% CI: 0.80--0.87) ([Figure 6](#f6-ott-12-479){ref-type="fig"}). [Figure 7](#f7-ott-12-479){ref-type="fig"} shows Fagan's nomogram of likelihood ratios, which was used to determine the post-test probabilities that resulted from different pre-test probabilities. As shown in [Figure 7](#f7-ott-12-479){ref-type="fig"}, when miR-210 assays were tested for all individuals with a 50% pre-test probability of having cancer, a positive result would increase the post-test probability of having cancer to 78%, while a negative result would decrease the post-test probability to 25%. Thus, miR-210 can be applied as a noninvasive biomarker to supplement existing diagnostic methods. As shown in [Figure 8](#f8-ott-12-479){ref-type="fig"}, an HSROC curve was constructed. The hierarchical summary operating point estimate of sensitivity and specificity was 0.74 (95% CI: 0.68--0.79) and 0.79 (95% CI: 0.74--0.83), respectively. The estimated value of β was −0.087 (95% CI: −0.55--0.38), the value of z was −0.37, and the *P*-value was 0.75, implying that the SROC curve was not symmetrical. The value of Lambda was 2.41 (95% CI: 2.03--2.79). All of these results revealed that miR-210 had relatively moderate accuracy in distinguishing cancer patients from all other individuals.

Meta-regression and robustness tests
------------------------------------

In order to find potential sources of heterogeneity, we performed a meta-regression analysis based on variables including the number of cases (yes ≥60, no \<60) and controls (yes ≥60, no \<60), cancer type, sample type (blood-based: serum, non-blood-based: sputum, urine, pancreatic juice, fecal matter), normalizer, and ethnicity. As shown in [Figure 9](#f9-ott-12-479){ref-type="fig"}, several variables including normalizer (U6), ethnicity (mixed: Caucasian/African), the number of cases (yes ≥60, no \<60), and cancer type (RCC, LC, PAAD) had a large effect on sensitivity. However, all variables had a great impact on specificity. Therefore, we then conducted subgroup analyses based on these factors. All results are presented in [Table 4](#t4-ott-12-479){ref-type="table"}. Goodness-of-fit and bivariate normality analyses ([Figure 10A and B](#f10-ott-12-479){ref-type="fig"}) showed that the bivariate model was moderately robust. Influence analysis identified four outliers, while three outliers were found through outlier detection ([Figure 10C and D](#f10-ott-12-479){ref-type="fig"}). After comprehensive consideration, we decided to exclude these three outliers (①⑨) and retain the fourth outlier (㉑). After exclusion, there was no significant change between these results and the overall results ([Table 2](#t2-ott-12-479){ref-type="table"}).

Threshold effect and heterogeneity
----------------------------------

Both the ROC plane and Spearman rank correlation coefficient were conducted to evaluate the threshold effect because of differences among cut-off values. The ROC plane was generated using Stata 13.0, and displayed a non-typical shoulder arm appearance, indicating that there was no threshold effect ([Figure 11A](#f11-ott-12-479){ref-type="fig"}). The Spearman correlation coefficient was −0.15 (*P*=0.02), suggesting that there was no threshold effect. The I[@b2-ott-12-479] of the heterogeneity tests of sensitivity and specificity were 96.95% and 96.95%, respectively, indicating significant heterogeneity. Therefore, meta-regression analysis and subgroup analyses were used to explore potential sources of heterogeneity in sensitivity and specificity.

Publication bias
----------------

Deeks' funnel plot asymmetry test was used to explore potential publication bias. The *P*-value of the linear regression was 0.09, suggesting that there was no publication bias ([Figure 11B](#f11-ott-12-479){ref-type="fig"}).

Discussion
==========

With the rapid development of next-generation sequencing technology, a large number of genes have been identified to be dysregulated during expression and involved in the occurrence and development of tumors. In recent years, miRNAs have been identified to function as regulators of gene expression that contribute to tumorigenesis and tumor progression.[@b20-ott-12-479] Since miRNAs can be easily collected from body fluids such as plasma, serum, urine, and secretions using noninvasive procedures, accumulating evidence suggests that body fluid-based miRNAs could function as potential novel and noninvasive biomarkers for the detection and diagnosis of cancer.[@b21-ott-12-479],[@b22-ott-12-479] miR-210 is an miRNA that has been found to be up-regulated in various cancers compared with adjacent normal tissues.[@b12-ott-12-479],[@b23-ott-12-479],[@b24-ott-12-479] A large number of studies have revealed that miR-210 acts as an oncogene to promote tumor development and progression via different signaling pathways, including the NF-κB signaling pathway.[@b25-ott-12-479],[@b26-ott-12-479] Many studies have explored the possible clinical usage of miR-210 in detecting and diagnosing cancers. However, the overall diagnostic accuracy of miR-210 is inconsistent in the literature due to the inescapable limitations of each study. Although two previous meta-analyses about the diagnostic significance of miR-210 in the detection of cancer have already been published several years ago, there are some defects in these studies. To avoid the limitations mentioned previously, we conducted this meta-analysis to derive a more reliable conclusion of the overall accuracy of miR-210 in the detection and diagnosis of cancer.

The pooled overall sensitivity and specificity of the studies were 0.74 (95% CI: 0.68--0.79) and 0.79 (95% CI: 0.74--0.83), respectively ([Figure 3](#f3-ott-12-479){ref-type="fig"}). The I[@b2-ott-12-479] values for sensitivity and specificity were 88.07% (95% CI: 84.69--91.44) and 79.44% (95% CI: 72.67--86.22) respectively, suggesting significant heterogeneity in sensitivity and specificity. Therefore, meta-regression analysis and subgroup analysis were used to explore potential sources of heterogeneity in sensitivity and specificity. We found that ethnicity, cancer type, normalizer, sample type, and the number of cases and controls had great influence on inter-study heterogeneity, which can be seen in [Figure 9](#f9-ott-12-479){ref-type="fig"}. Therefore, we then conducted subgroup analyses of these factors. All results are presented in [Table 4](#t4-ott-12-479){ref-type="table"}. The pooled PLR and NLR were 3.57 (95% CI: 2.85--4.47) and 0.32 (95% CI: 0.26--0.40), respectively. The DOR was 10.98 (95% CI: 7.55--15.98). The area under the SROC curve was 0.84 (95% CI: 0.80--0.87). The hierarchical summary operating point estimate of sensitivity and specificity were 0.74 (95% CI: 0.68--0.79) and 0.79 (95% CI: 0.74--0.83), respectively. The estimated value of β was −0.087 (95% CI: −0.55--0.38), the value of z was −0.37, and the *P*-value was 0.75, implying that the SROC curve was not symmetric. The value of lambda was 2.41 (95% CI: 2.03--2.79). Furthermore, Fagan's nomogram was used to determine post-test probabilities resulting from different pretest probabilities to explore the clinical value of miR-210. As shown in [Figure 7](#f7-ott-12-479){ref-type="fig"}, when miR-210 assays were tested for all individuals with a pre-test probability of 50% to get cancer, a positive result would increase the post-test probability of having cancer to 78%, while a negative result would decrease the post-test probability to 25%. All of these results revealed that miR-210 had relatively moderate accuracy in distinguishing cancer patients from all other individuals.

Several limitations of this study should still be highlighted for a comprehensive and synthetic interpretation. First, a majority of eligible studies did not mention the stage of cancer. Therefore, the present study did not evaluate differences in the diagnostic accuracy of miR-210 in various cancers at different stages. Second, not all of the studies reported a cutoff value for miR-210, which largely contributed to potential sources of heterogeneity. Third, the sample types were inconsistent and included serum (19 studies), sputum (five studies), urine (three studies), pancreatic juice (one study), and fecal matter (one study). Due to the limited study size of each individual study, subgroup analysis by sample type could not be explored. Fourth, the studies included were not randomly compared tests, implying that subjective judgement may exist, possibly leading to a low study quality QUADAS-2 score. Despite these limitations, our study is the most comprehensive meta-analysis to evaluate the diagnostic value of miR-210 for patients with various cancers.

Conclusion
==========

To summarize, the results of this meta-analysis revealed that miR-210 had relatively moderate accuracy in distinguishing patients with various cancers from all other individuals, and provided comprehensive and synthetic evidence of miR-210 as a potential noninvasive biomarker in the detection and diagnosis of cancer. However, well-designed prospective studies with large sample sizes of different groups of the population are urgently needed to confirm our findings.

This research was supported by Health Care 3F Project of Shenzhen (Shanghai Jiao Tong University-Peking University Shenzhen Hospital, Academician Wenjiang Ding's Team).

**Disclosure**

The authors report no conflicts of interest in this work.

![The expression of miR-210 was up-regulated in various cancers compared with adjacent normal tissues.\
**Note:** The expression of both miR-210-3p (**A**) and miR-210-5p (**B**) were up-regulated in BLCA, KIRC, KIRP, BRCA, LUSC, and STAD (^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001).\
**Abbreviations:** BLCA, bladder cancer; BRCA, breast cancer; KIRC, kidney clear cell carcinoma; KIRP, kidney papillary cell carcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic cancer; READ, rectal cancer; STAD, stomach cancer.](ott-12-479Fig1){#f1-ott-12-479}

![Flow diagram of the selection process of studies included.\
**Abbreviation:** CNKI, China National Knowledge Infrastructure.](ott-12-479Fig2){#f2-ott-12-479}

![Forest plots of sensitivity and specificity of the overall results.](ott-12-479Fig3){#f3-ott-12-479}

![Forest plots of the positive likelihood ratio and the negative likelihood ratio of miR-210 in the diagnosis of cancers.\
Abbreviation: DLR, diagnostic likelihood ratio.](ott-12-479Fig4){#f4-ott-12-479}

![Forest plots of the diagnostic OR of miR-210 in the diagnosis of cancers.](ott-12-479Fig5){#f5-ott-12-479}

![Summary receiver operator characteristic (SROC) curve of miR-210 in the diagnosis of cancers.\
Notes: (A) Overall result including the outliers. (B) Outliers excluded. The numerals in the figure correspond with studies listed in [Table 2](#t2-ott-12-479){ref-type="table"}.\
Abbreviations: SENS, sensitivity; SPEC, specificity.](ott-12-479Fig6){#f6-ott-12-479}

![Fagan's nomogram for assessing post-test probabilities.\
Abbreviations: Prob, probability; LR, likelihood ratio; pos, positive; neg, negative.](ott-12-479Fig7){#f7-ott-12-479}

![Hierarchical summary receiver operator characteristic (HSROC) curve of miR-210 in the diagnosis of cancers.](ott-12-479Fig8){#f8-ott-12-479}

![Univariable meta-regression analysis for sensitivity and specificity of miR-210 in the diagnosis of cancers.\
Note: Factors marked with an asterisk are potential sources of heterogeneity.\
Abbreviations: LC, lung cancer; PAAD, pancreatic cancer; RCC, renal cell carcinoma.](ott-12-479Fig9){#f9-ott-12-479}

![Influence analysis and outlier detection.\
Notes: (A) Goodness-of-fit, (B) bivariate normality, (C) influence analysis, and (D) outlier detection. The numerals in the figure correspond with studies listed in [Table 2](#t2-ott-12-479){ref-type="table"}.](ott-12-479Fig10){#f10-ott-12-479}

![(A) Receiver operating characteristic (ROC) plane to assess threshold effects; (B) Deeks' funnel plot asymmetry test to assess publication bias.\
Note: The numerals in the figure correspond with studies listed in [Table 2](#t2-ott-12-479){ref-type="table"}.](ott-12-479Fig11){#f11-ott-12-479}

###### 

Correlation between miR-210 expression and clinicopathological characteristics of patients with various cancers

  Cancer type   miR-210      Sample type   OS        RFS                                             
  ------------- ------------ ------------- --------- ------------- ---------- -------- ------------- --------
                                                                                                     
  BLCA          miR-210-3p   9.0667        3.4918    1.05509E-11   0.0664     0.7967   0.09716       0.7553
                miR-210-5p   1.1792        0.3952    1.9562E-05    0.3517     0.5532   0.005649      0.9401
  KIRC          miR-210-3p   11.4017       7.8702    0             0.003842   0.9506   4.093         0.0431
                miR-210-5p   1.5756        0.671     2.64233E-14   0.5693     0.4505   0.242         0.6228
  KIRP          miR-210-3p   9.0781        7.1327    4.12448E-11   2.363      0.1242   0.1231        0.7257
                miR-210-5p   1.0426        0.5412    2.96369E-07   1.064      0.3022   0.008749      0.9255
  PAAD          miR-210-3p   8.4673        7.5524    0.263         3.045      0.081    2.722         0.099
                miR-210-5p   0.9083        0.6031    0.399         0.7011     0.4024   0.3621        0.5473
  BRCA          miR-210-3p   8.2153        5.7278    0             0.7134     0.3983   0.357         0.5502
                miR-210-5p   0.7765        0.33119   0.002         0.09328    0.7601   0.03927       0.8429
  READ          miR-210-3p   8.947         9.2383    0.587         1.42       0.2335   0.4132        0.5204
                miR-210-5p   0.7184        2.6834    0.000207331   1.013      0.3141   0.000004748   0.9983
  LUSC          miR-210-3p   10.8598       6.2018    0             0.5837     0.4449   1.147         0.2841
                miR-210-5p   1.4413        0.5197    4.44089E-16   0.1682     0.6817   0.7755        0.3785
  STAD          miR-210-3p   7.8327        6.1979    0.000215803   1.782      0.1819   2.747         0.0974
                miR-210-5p   0.7643        0.5017    0.003617978   0.09764    0.7547   0.03605       0.8494

**Abbreviations:** BRCA, breast cancer; BLCA, bladder cancer; KIRC, kidney clear cell carcinoma; KIRP, kidney papillary cell carcinoma; LUSC, lung squamous cell carcinoma; OS, overall survival; PAAD, pancreatic cancer; READ, rectal cancer; RFS, relapse-free survival; STAD, stomach cancer.

###### 

Characteristics of the included studies

  First author                         Year   Country   Ethnicity   Cancer type   Normalizer      Sample type        Test method   Cut-off   Cases/controls   TP    FP   FN   TN
  ------------------------------------ ------ --------- ----------- ------------- --------------- ------------------ ------------- --------- ---------------- ----- ---- ---- -----
                                                                                                                                                                              
  1 Yang et al[@b27-ott-12-479]        2015   China     Asian       BLCA          miR-16          Serum              qRT-PCR       22.37     168/104          164   32   4    72
  2 Eissa et al[@b28-ott-12-479]       2015   Egypt     African     BLCA          U6              Urinary            qRT-PCR       1.17      94/116           72    8    22   108
  3 Eissa et al[@b29-ott-12-479]       2015   Egypt     African     BLCA          U6              Urinary            qRT-PCR       NA        188/180          134   16   54   164
  4 Li et al[@b30-ott-12-479]          2017   China     Asian       RCC           miR-39          Urinary            qRT-PCR       0.0002    75/45            43    9    32   36
  5 Zhang et al[@b31-ott-12-479]       2016   China     Asian       RCC           U6              Serum              qRT-PCR       NA        82/80            57    30   25   50
  6 Iwamoto et al[@b32-ott-12-479]     2013   Japan     Asian       RCC           miR-16          Serum              qRT-PCR       NA        34/23            22    4    12   19
  7 Zhao et al[@b33-ott-12-479]        2013   France    Caucasian   RCC           5s rRNA         Serum              qRT-PCR       NA        68/42            55    9    13   33
  8 Li et al[@b34-ott-12-479]          2015   China     Asian       RCC           U6              Serum              qRT-PCR       NA        22/20            18    4    4    16
  9 Zhu et al[@b35-ott-12-479]         2016   China     Asian       NSCLC         U6              Serum              qRT-PCR       0.1069    112/40           38    0    74   40
  10 Wang et al[@b36-ott-12-479]       2016   China     Asian       NSCLC         miR-16          Serum              qRT-PCR       3.34      59/59            44    15   15   44
  11 Li et al[@b37-ott-12-479]         2013   China     Asian       NSCLC         miR-16          Serum              qRT-PCR       1.307     60/30            47    8    13   22
  12 Shen et al[@b38-ott-12-479]       2010   USA       Mixed       NSCLC         miR-16          Serum              qRT-PCR       NA        58/29            43    9    15   20
  13 Shen et al[@b39-ott-12-479]       2011   USA       Mixed       NSCLC         miR-16          Serum              qRT-PCR       NA        32/33            18    9    14   24
  14 Anjuman et al[@b40-ott-12-479]    2013   USA       Mixed       NSCLC         U6              Sputum             qRT-PCR       NA        39/42            27    10   12   32
  15 Xing et al[@b41-ott-12-479]       2015   USA       Mixed       LC            miR-16          Sputum             qRT-PCR       36.56     60/62            45    9    15   53
  16 Shen et al[@b42-ott-12-479]       2014   USA       Mixed       LC            U6              Sputum             qRT-PCR       NA        66/68            43    18   23   50
  17 Xing et al[@b43-ott-12-479]       2010   USA       Mixed       LC            U6              Sputum             qRT-PCR       1.64      48/48            28    10   20   38
  18 Li et al[@b44-ott-12-479]         2014   USA       Mixed       LC            U6              Sputum             qRT-PCR       NA        35/40            20    4    15   36
  19 Wang et al[@b45-ott-12-479]       2014   USA       Mixed       PAAD          U6              Pancreatic Juice   qRT-PCR       NA        50/19            38    1    12   18
  20 Wang et al[@b46-ott-12-479]       2009   USA       Caucasian   PAAD          miR-16          Serum              qRT-PCR       NA        28/19            12    5    16   14
  21 Kojima et al[@b47-ott-12-479]     2015   Japan     Asian       PAAD          NA              Serum              microarray    NA        100/21           59    15   41   6
  22 Ren et al[@b48-ott-12-479]        2012   China     Asian       PAAD          miR-16          Fecal              qRT-PCR       1.54      29/13            25    4    4    9
  23 Chen et al[@b49-ott-12-479]       2015   China     Asian       PAAD          miR-39          Serum              qRT-PCR       NA        37/40            30    3    7    37
  24 Pan et al[@b50-ott-12-479]        2014   China     Asian       PAAD          miR-39          Serum              qRT-PCR                 30/26            21    4    9    22
  25 Madhavan et al[@b51-ott-12-479]   2012   Germany   Caucasian   BRCA          miR-39          Serum              qRT-PCR       NA        61/76            51    14   10   62
                                                                                                                                             72/76            45    37   27   39
  26 Wang et al[@b52-ott-12-479]       2016   China     Asian       CRC           miR-191-5p/U6   Serum              qRT-PCR       1.1476    268/102          200   27   68   75
  27 Fang et al[@b53-ott-12-479]       2015   China     Asian       CRC           U6              Serum              qRT-PCR       38.31     48/40            40    12   8    28
  28 Qi et al[@b54-ott-12-479]         2016   China     Asian       GC            U6              Serum              qRT-PCR       NA        100/100          86    18   14   82
  29 Lai et al[@b55-ott-12-479]        2015   China     Asian       Glioma        miR-16          Serum              qRT-PCR       2.259     136/50           124   14   12   36
  30 Xie et al[@b56-ott-12-479]        2015   China     Asian       Leukemia      miR-16          Serum              qRT-PCR       NA        45/30            41    6    4    24

**Abbreviations:** BLCA, bladder cancer; BRCA, breast cancer; CRC, colorectal carcinoma; FN, false negative; FP, false positive; GC, gastric cancer; LC, lung cancer; Mixed, Caucasian/African; NA, ; NSCLC, non-small-cell lung cancer; PAAD, pancreatic cancer; RCC, renal cell carcinoma; TN, true negative; TP, true positive.

###### 

QUADAS-2 assessment for the eligible studies

  Studies                          Risk of bias                                       
  -------------------------------- -------------- --- --- --- --- --- --- --- --- --- ---
                                                                                      
  Yang 2015[@b21-ott-12-479]       Y              U   U   N   N   Y   Y   Y   Y   Y   Y
  Eissa 2015[@b28-ott-12-479]      Y              N   N   N   N   Y   Y   Y   Y   Y   Y
  Eissa 2015[@b29-ott-12-479]      Y              N   N   N   N   Y   Y   Y   Y   Y   Y
  Li et al 2017[@b30-ott-12-479]   U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Zhang 2016[@b31-ott-12-479]      U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Iwamoto 2013[@b32-ott-12-479]    Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Zhao 2013[@b33-ott-12-479]       U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Li 2015[@b34-ott-12-479]         U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Zhu 2016[@b35-ott-12-479]        Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Wang 2016[@b36-ott-12-479]       Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Li 2013[@b37-ott-12-479]         Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Shen 2010^38^                    U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Shen 2011[@b39-ott-12-479]       U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Anjuman 2013[@b40-ott-12-479]    U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Xing 2015[@b41-ott-12-479]       U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Shen 2014[@b42-ott-12-479]       U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Xing 2010^43^                    Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Li 2014[@b44-ott-12-479]         U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Wang 2014[@b45-ott-12-479]       U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Wang 2009[@b46-ott-12-479]       Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Kojima 2015[@b47-ott-12-479]     Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Ren 2012[@b48-ott-12-479]        Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Chen 2015[@b49-ott-12-479]       U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Pan 2014[@b50-ott-12-479]        Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Madhavan 2012[@b51-ott-12-479]   U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Wang 2016[@b52-ott-12-479]       Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Fang 2015[@b53-ott-12-479]       U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Qi 2012[@b54-ott-12-479]         U              N   U   N   N   Y   Y   Y   Y   Y   Y
  Lai 2015[@b55-ott-12-479]        Y              N   U   N   N   Y   Y   Y   Y   Y   Y
  Xie 2012[@b56-ott-12-479]        U              N   U   N   N   Y   Y   Y   Y   Y   Y

**Notes:** ① Was a consecutive or random sample of patients enrolled? ② Was a case control design avoided? ③ Did the study avoid inappropriate exclusions? ④ Were the index test results interpreted without knowledge of the results of the reference standard? ⑤ If a threshold was used, was it prespecified? ⑥ Is the reference standard likely to correctly classify the target condition? ⑦ Were the reference standard results interpreted without knowledge of the results of the index test? ⑧ Was there an appropriate interval between index tests and reference standard? ⑨ Did all patients receive a reference standard? ⑩ Did all patients receive the same reference standard? ⑪ Were all patients included in the analysis? N for "no," Y for "yes," U for "unclear."

**Abbreviation:** QUADAS-2, Quality Assessment of Diagnostic Accuracy Studies-2.

###### 

Summary results of subgroup analysis for miR-210 in the diagnosis of cancer

  Variable           Number of studies   SEN (95% CI)        SPE (95% CI)   PLR (95% CI)   NLR (95% CI)        DOR (95% CI)   AUC (95% CI)                                                     
  ------------------ ------------------- ------------------- -------------- -------------- ------------------- -------------- -------------- ---------------- ------------------- ------------ -------------------
                                                                                                                                                                                               
  Ethnicity                                                                                                                                                                                    
   Asian             17                  0.78 (0.70, 0.85)   93.05          0              0.77 (0.70, 0.83)   73.24          0              3.5 (2.6, 4.7)   0.28 (0.20, 0.40)   12 (7, 21)   0.85 (0.81, 0.87)
   Mixed             8                   0.68 (0.62, 0.72)   35.41          0.12           0.80 (0.74, 0.85)   73.05          0              3.4 (2.5, 4.4)   0.41 (0.34, 0.49)   8 (5, 13)    0.77 (0.73, 0.81)
   Caucasian         4                   0.71 (0.54, 0.83)   85.95          0              0.70 (0.55, 0.82)   84.09          0              2.4 (1.3, 4.4)   0.42 (0.22, 0.79)   6 (2, 19)    0.76 (0.72, 0.80)
  Cancer type                                                                                                                                                                                  
   NSCLC             6                   0.66 (0.52, 0.77)   90.64          0              0.81 (0.66, 0.90)   65.29          0.01           3.4 (2.1, 5.6)   0.42 (0.32, 0.55)   8 (5, 13)    0.79 (0.75, 0.82)
   LC                4                   0.65 (0.58, 0.72)   33.83          0.21           0.82 (0.74, 0.87)   45.88          0.14           3.5 (2.4, 5.1)   0.43 (0.34, 0.53)   8 (5, 14)    0.75 (0.71, 0.79)
   RCC               5                   0.70 (0.61, 0.78)   65.79          0.02           0.75 (0.66, 0.83)   51.99          0.08           2.9 (2.0, 4.1)   0.39 (0.29, 0.53)   7 (4, 13)    0.79 (0.76, 0.83)
   PAAD              6                   0.71 (0.59, 0.80)   80.31          0              0.79 (0.57, 0.92)   86.89          0              3.4 (1.4, 8.4)   0.37 (0.23, 0.61)   9 (2, 35)    0.79 (0.75, 0.82)
  Normalizer                                                                                                                                                                                   
   miR-16            11                  0.80 (0.68, 0.88)   89.17          0              0.75 (0.71, 0.80)   0              0.63           3.3 (2.7, 3.9)   0.26 (0.16, 0.43)   12 (7, 23)   0.78 (0.74, 0.82)
   U6                10                  0.70 (0.62, 0.77)   88.08          0              0.85 (0.77, 0.91)   82.63          0              4.8 (3.1, 7.3)   0.35 (0.37, 0.45)   14 (8, 23)   0.84 (0.81, 0.87)
   miR-39            4                   0.72 (0.61, 0.80)   77.34          0              0.80 (0.65, 0.89)   88.86          0              3.5 (1.8, 6.8)   0.36 (0.23, 0.56)   10 (3, 29)   0.81 (0.77, 0.84)
  Sample type                                                                                                                                                                                  
   Blood-based       21                  0.76 (0.68, 0.83)   91.6           0              0.76 (0.69, 0.81)   74.9           0              3.1 (2.4, 4.1)   0.31 (0.23, 0.43)   10 (6, 17)   0.83 (0.79, 0.86)
   Non-blood-based   5                   0.69 (0.64, 0.73)   53.26          0.02           0.85 (0.80, 0.90)   68.14          0              4.7 (3.3, 6.8)   0.31 (0.37, 0.44)   13 (8, 22)   0.80 (0.77, 0.84)
  Case                                                                                                                                                                                         
   ≥60               16                  0.76 (0.67, 0.83)   92.81          0              0.78 (0.69, 0.85)   88.03          0              3.5 (2.4, 5.1)   0.31 (0.22, 0.43)   11 (6, 20)   0.84 (0.80, 0.87)
   \<60              15                  0.72 (0.66, 0.78)   67.18          0              0.79 (0.75, 0.83)   21.69          0.21           3.5 (2.8, 4.4)   0.35 (0.27, 0.44)   10 (7, 15)   0.83 (0.79, 0.86)
  Control                                                                                                                                                                                      
   ≥60               12                  0.77 (0.66, 0.86)   94.19          0              0.81 (0.71, 0.88)   89.04          0              4.1 (2.7, 6.2)   0.28 (0.18, 0.42)   15 (8, 27)   0.86 (0.83, 0.89)
   \<60              19                  0.72 (0.66, 0.77)   71.04          0              0.78 (0.72, 0.83)   61.68          0              3.2 (2.5, 4.2)   0.36 (0.29, 0.45)   9 (6, 14)    0.81 (0.78, 0.85)
  Overall            31                  0.74 (0.68, 0.79)   88.07          0              0.79 (0.74, 0.83)   79.44          0              3.6 (2.8, 4.5)   0.32 (0.26, 0.40)   11 (8, 16)   0.84 (0.80, 0.87)
  Outlier excluded   28                  0.74 (0.70, 0.78)   73.05          0              0.79 (0.75, 0.83)   73.91          0              3.6 (2.9, 4.4)   0.32 (0.27, 0.39)   11 (8, 16)   0.84 (0.80, 0.87)

**Abbreviations:** DOR, diagnostic OR; LC, lung cancer; NLR, negative likelihood ratio; NSCLC, non-small-cell lung cancer; PAAD, pancreatic cancer; PH, P-value of heterogeneity test; PLR, positive likelihood ratio; RCC, renal cell carcinoma; SEN, sensitivity; SPE, specificity.

[^1]: These authors contributed equally to this work
